<SEC-DOCUMENT>0001999371-25-015943.txt : 20251023
<SEC-HEADER>0001999371-25-015943.hdr.sgml : 20251023
<ACCEPTANCE-DATETIME>20251023160717
ACCESSION NUMBER:		0001999371-25-015943
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251023
DATE AS OF CHANGE:		20251023

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SUTRO BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001382101
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452441988
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90656
		FILM NUMBER:		251413088

	BUSINESS ADDRESS:	
		STREET 1:		111 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-392-8412

	MAIL ADDRESS:	
		STREET 1:		111 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUTRO BIOPHARMA INC
		DATE OF NAME CHANGE:	20061127

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Affinity Asset Advisors, LLC
		CENTRAL INDEX KEY:			0001773195
		ORGANIZATION NAME:           	
		EIN:				821567490
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		450 PARK AVENUE
		STREET 2:		SUITE 1403
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		917-826-4533

	MAIL ADDRESS:	
		STREET 1:		450 PARK AVENUE
		STREET 2:		SUITE 1403
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Affinity Asset Advisors, LLC -->
          <cik>0001773195</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>10/16/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001382101</issuerCik>
        <issuerName>SUTRO BIOPHARMA, INC.</issuerName>
        <issuerCusip>869367102</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>111 OYSTER POINT BLVD.</com:street1>
          <com:city>SOUTH SAN FRANCISCO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Affinity Healthcare Fund, LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>6583772.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>6583772.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6583772.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.77</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Affinity Asset Advisors, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>6583772.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>6583772.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6583772.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.77</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>SUTRO BIOPHARMA, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>111 Oyster Point Blvd. South San Franciso, CA 94080</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Affinity Healthcare Fund, LP
Affinity Asset Advisors, LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>450 Park Avenue
Suite 1403
New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein.  As of October 23, 2025, the Fund beneficially owned an aggregate of 6,583,772 shares of Common Stock of the Issuer, or 7.77% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of the securities reported herein owned by the Fund by virtue of its position as investment manager of the Fund.  The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of the securities reported herein.</amountBeneficiallyOwned>
        <classPercent>The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 84,774,177 shares of Common Stock of the Issuer outstanding as of August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Affinity Healthcare Fund, LP - 0.00
Affinity Asset Advisors, LLC - 0.00</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Affinity Healthcare Fund, LP - 6,583,772 shares of Common Stock
Affinity Asset Advisors, LLC - 6,583,772 shares of Common Stock</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Affinity Healthcare Fund, LP - 0.00
Affinity Asset Advisors, LLC - 0.00</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Affinity Healthcare Fund, LP - 6,583,772 shares of Common Stock
Affinity Asset Advisors, LLC - 6,583,772 shares of Common Stock</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Affinity Healthcare Fund, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Andrew Weinstein</signature>
        <title>Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer</title>
        <date>10/23/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Affinity Asset Advisors, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Andrew Weinstein</signature>
        <title>Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer</title>
        <date>10/23/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
